26/05/2022 – AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) Download PDF Post navigationPreviousPrevious post:Annual financial results as of 31 December, 2021NextNext post:Publication of results from the positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in Journal of Asthma and AllergyRelated PostsPublication of results from the positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in Journal of Asthma and AllergyJune 7, 2022Annual financial results as of 31 December, 2021April 29, 2022Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19April 28, 2022Communication from AB Science following the decision of the Enforcement Committee of the French market regulator (AMF)March 29, 2022Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indicationsFebruary 28, 2022Financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrantsFebruary 28, 2022
Publication of results from the positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in Journal of Asthma and AllergyJune 7, 2022
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19April 28, 2022
Communication from AB Science following the decision of the Enforcement Committee of the French market regulator (AMF)March 29, 2022
Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indicationsFebruary 28, 2022
Financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrantsFebruary 28, 2022
